Insider Transactions Reported by 30 Insiders of Zymeworks Inc.

Symbol: ZYME on Nasdaq
Location: Middletown, DE

Quick Takeaways

ZYME - Zymeworks Inc. has 30 insiders with reported activity on this page.
Net insider value flow over the last year: -$3,407,347.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $1,266,404; sell value: $4,673,751.
Net share flow: -77,752.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$3,407,347.

Buys

$1,266,404

Shares: 110,181

Insiders: 1

Sells

$4,673,751

Shares: 187,933

Insiders: 4

Net

-$3,407,347

Shares: -77,752

Insiders: -3

Window (months)	Buy shares	Sell shares	Buy $	Sell $	Net $
0-3	0	0	$0	$0	$0
3-6	0	187,933	$0	$4,673,751	-$4,673,751
6-9	0	0	$0	$0	$0
9-12	110,181	0	$1,266,404	$0	+$1,266,404

Zymeworks Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
EcoR1 Capital, LLC	Director, 10%+ Owner	$341,953,624	+$635,586	+0.19%	Mixed	26 Jun 2025
Oleg Nodelman	Director, 10%+ Owner	$218,112,518			Mixed	17 Feb 2025
Redmile Group, LLC	10%+ Owner	$30,584,956			Filing P/S	13 Oct 2022
Kenneth Galbraith	Chair & CEO, Director	$8,008,729	-$3,337,971	-29%	Mixed	12 Jan 2026
Gregory Austin Ciongoli	Director	$5,938,470			Mixed	12 Jan 2026
Mark Hollywood	EVP & Chief Operating Officer	$3,013,602	-$138,762	-4.4%	Filing P/S	12 Jan 2026
Paul Andrew Moore	Chief Scientific Officer	$1,890,573	-$721,457	-28%	Mixed	12 Jan 2026
Smith Jeffrey T. L.	EVP & Chief Medical Officer	$1,396,540	-$475,561	-25%	Mixed	12 Jan 2026
Leone D. Patterson	EVP, Chief Bus & Fin Officer	$795,819			Mixed	06 Jan 2026
Christopher Astle	SVP & Chief Financial Officer	$409,403			Mixed	05 Jan 2024
Neil Josephson	Chief Medical Officer	$294,084			Mixed	10 Nov 2022
Mr. Neil Klompas	President & COO	$229,258			Mixed	10 Mar 2023
Nancy Davidson	Director				Mixed	10 Dec 2024
Kelvin Neu	Director				Mixed	12 Jan 2026
Robert E. Landry	Director				Mixed	12 Jan 2026
Brian N. Cherry	Director				Mixed	12 Jan 2026
Kristin Stafford	EVP, Chief Financial Officer				Mixed	06 Apr 2026
Sabeen Mekan	SVP & Chief Medical Officer				Mixed	01 Feb 2026
Adam Schayowitz	EVP, Head of Research & Development				Mixed	09 Apr 2026
Alessandra Cesano	Director				Mixed	12 Jan 2026
Troy Cox	Director				Mixed	10 Dec 2024
Neil Gallagher	Director				Mixed	10 Dec 2024
Scott Platshon	EVP, Chief Business Officer				Mixed	09 Apr 2026
Kenneth J. Hillan	Director				Mixed	07 Dec 2023
Lota S. Zoth	Director				Mixed	21 Dec 2022
Susan Mahony	Director				Mixed	12 Jan 2026
Carlos Campoy	Director				Mixed	12 Jan 2026
Derek John Michael Miller	Director				Mixed	10 Dec 2024
Natalie Sacks	Director				Mixed	21 Dec 2022
Hollings Renton	Director				Mixed	07 Dec 2023

Top shareholders of Zymeworks Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
EcoR1 Capital, LLC	13F 13D/G 3/4/5	Company · Director, 10%+ Owner	31% from 13D/G	22,970,388	$604,810,316	—	31 Dec 2025	13F 13D/G 3/4/5
Oleg Nodelman	3/4/5	Director, 10%+ Owner	— class O/S missing	15,720,161	$218,112,518	—	17 Feb 2025	3/4/5
Rubric Capital Management LP	13D/G 13F	Company	7.7%	5,750,000	$153,065,000	$0	31 Dec 2025	13D/G 13F
BlackRock, Inc.	13F 13D/G	Company	4.8% from 13D/G	4,595,548	$121,000,779	—	31 Dec 2025	13F 13D/G
BVF INC/IL	13F	Company	5.4%	3,938,641	$103,704,418	—	31 Dec 2025	13F
PERCEPTIVE ADVISORS LLC	13D/G 13F	Company	5.4%	3,974,579	$99,527,035	$0	08 Apr 2026	13D/G 13F
MORGAN STANLEY	13F 13D/G	Company	3.4% from 13D/G	2,593,080	$68,275,801	—	31 Dec 2025	13F 13D/G
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	5.2%	3,938,641	$67,271,988	$0	30 Sep 2025	13D/G
Redmile Group, LLC	13D/G 3/4/5 13F	10%+ Owner · Company	4.9%	3,705,750	$63,294,210	-$7,598,499	30 Sep 2025	13D/G 3/4/5 13F
VANGUARD GROUP INC	13F	Company	3.2%	2,328,727	$61,315,382	—	31 Dec 2025	13F
BNP Paribas Asset Management Holding S.A.	13F	Company	2.5%	1,822,048	$47,975,000	—	31 Dec 2025	13F
Siren, L.L.C.	13F	Individual	2.3%	1,680,121	$44,237,586	—	31 Dec 2025	13F
DEUTSCHE BANK AG\	13F	Company	2.2%	1,595,833	$42,018,282	—	31 Dec 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	1.6%	1,159,215	$30,523,404	—	31 Dec 2025	13F
Nextech Invest, Ltd.	13F	Company	1.5%	1,113,946	$29,330,198	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	1.4%	1,037,642	$27,321,114	—	31 Dec 2025	13F
Capricorn Fund Managers Ltd	13F	Company	1.4%	1,022,840	$26,931,377	—	31 Dec 2025	13F
Vestal Point Capital, LP	13F	Company	1.2%	865,000	$22,775,450	—	31 Dec 2025	13F
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	13F	Company	0.95%	700,002	$18,431,053	—	31 Dec 2025	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.9%	663,546	$17,471,166	—	31 Dec 2025	13F
Nuveen, LLC	13F	Company	0.88%	648,326	$17,070,424	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.88%	647,970	$17,060,446	—	31 Dec 2025	13F
Assenagon Asset Management S.A.	13F	Company	0.88%	647,374	$17,045,357	—	31 Dec 2025	13F
FMR LLC	13F	Company	0.76%	560,086	$14,747,059	—	31 Dec 2025	13F
Prosight Management, LP	13F	Company	0.72%	530,393	$13,965,248	—	31 Dec 2025	13F
Qube Research & Technologies Ltd	13F	Company	0.64%	474,290	$12,488,056	—	31 Dec 2025	13F
ALGERT GLOBAL LLC	13F	Company	0.58%	423,646	$11,155,000	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.57%	420,207	$11,064,051	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.52%	381,621	$10,048,081	—	31 Dec 2025	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.44%	320,261	$8,432,472	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.42%	307,979	$8,109,087	—	31 Dec 2025	13F
Kenneth Galbraith	3/4/5	Chair & CEO, Director	— mixed-class rows	808,842 mixed-class rows	$8,008,729	-$3,337,971	12 Jan 2026	3/4/5
Schonfeld Strategic Advisors LLC	13F	Company	0.39%	288,571	$7,598,072	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.38%	278,854	$7,342,226	—	31 Dec 2025	13F
Invesco Ltd.	13F	Company	0.35%	257,580	$6,782,081	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.35%	255,351	$6,723,392	—	31 Dec 2025	13F
PICTON MAHONEY ASSET MANAGEMENT	13F	Company	0.33%	244,798	$6,445,531	—	31 Dec 2025	13F
Hillsdale Investment Management Inc.	13F	Company	0.32%	237,922	$6,264,487	—	31 Dec 2025	13F
Gregory Austin Ciongoli	3/4/5	Director	— mixed-class rows	512,700 mixed-class rows	$5,938,470	—	12 Jan 2026	3/4/5
Granahan Investment Management, LLC	13F	Company	0.3%	224,408	$5,908,663	—	31 Dec 2025	13F
SummitTX Capital, L.P.	13F	Company	0.3%	224,268	$5,904,976	—	31 Dec 2025	13F
D. E. Shaw & Co., Inc.	13F	Company	0.3%	223,786	$5,892,285	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.3%	220,909	$5,816,534	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.3%	220,877	$5,815,691	—	31 Dec 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.28%	208,313	$5,484,873	—	31 Dec 2025	13F
RAYMOND JAMES FINANCIAL INC	13F	Company	0.25%	187,685	$4,941,747	—	31 Dec 2025	13F
SILVERCREST ASSET MANAGEMENT GROUP LLC	13F	Company	0.25%	181,790	$4,786,531	—	31 Dec 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.25%	181,705	$4,784,292	—	31 Dec 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.24%	176,088	$4,636,397	—	31 Dec 2025	13F
FEDERATED HERMES, INC.	13F	Company	0.21%	152,689	$4,020,302	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for Zymeworks Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Adam Schayowitz	ZYME	Performance Stock Unit	Award				76,000	76,000	09 Apr 2026	Direct
Adam Schayowitz	ZYME	Restricted Stock Unit	Award				47,000	47,000	09 Apr 2026	Direct
Adam Schayowitz	ZYME	Stock Option (Right to Buy)	Award				70,000	70,000	09 Apr 2026	Direct
Scott Platshon	ZYME	Performance Stock Unit	Award				76,000	76,000	09 Apr 2026	Direct
Scott Platshon	ZYME	Restricted Stock Unit	Award				47,000	47,000	09 Apr 2026	Direct
Scott Platshon	ZYME	Stock Option (Right to Buy)	Award				70,000	70,000	09 Apr 2026	Direct
Kristin Stafford	ZYME	Restricted Stock Unit	Award				169,000	119,000	06 Apr 2026	Direct
Kristin Stafford	ZYME	Stock Option (Right to Buy)	Award				178,000	178,000	06 Apr 2026	Direct
Mark Hollywood	ZYME	Common Stock	Sale	-4.4%	$138,762	$22.67	-6,120	132,913	12 Jan 2026	Direct
Mark Hollywood	ZYME	Common Stock	Options Exercise	14.6%			17,666	139,033	12 Jan 2026	Direct
Mark Hollywood	ZYME	Performance Stock Unit	Award				66,000	66,000	12 Jan 2026	Direct
Mark Hollywood	ZYME	Restricted Stock Unit	Award				47,000	47,000	12 Jan 2026	Direct
Mark Hollywood	ZYME	Stock Option (Right to Buy)	Award				70,000	70,000	12 Jan 2026	Direct
Mark Hollywood	ZYME	Restricted Stock Unit	Options Exercise	-33.3%			-17,666	35,334	12 Jan 2026	Direct
Brian N. Cherry	ZYME	Restricted Stock Unit	Award				15,400	15,400	12 Jan 2026	Direct
Brian N. Cherry	ZYME	Stock Option (Right to Buy)	Award				23,000	23,000	12 Jan 2026	Direct
Smith Jeffrey T. L.	ZYME	Common Stock	Sale	-25.8%	$211,090	$22.67	-9,310	26,708	12 Jan 2026	Direct
Smith Jeffrey T. L.	ZYME	Common Stock	Options Exercise	96.3%			17,666	36,018	12 Jan 2026	Direct
Smith Jeffrey T. L.	ZYME	Restricted Stock Unit	Options Exercise	-33.3%			-17,666	35,334	12 Jan 2026	Direct
Gregory Austin Ciongoli	ZYME	Restricted Stock Unit	Award				7,700	7,700	12 Jan 2026	Direct
Gregory Austin Ciongoli	ZYME	Stock Option (Right to Buy)	Award				11,500	11,500	12 Jan 2026	Direct
Kelvin Neu	ZYME	Restricted Stock Unit	Award				7,700	7,700	12 Jan 2026	Direct
Kelvin Neu	ZYME	Stock Option (Right to Buy)	Award				11,500	11,500	12 Jan 2026	Direct
Robert E. Landry	ZYME	Restricted Stock Unit	Award				7,700	7,700	12 Jan 2026	Direct
Robert E. Landry	ZYME	Stock Option (Right to Buy)	Award				11,500	11,500	12 Jan 2026	Direct
Alessandra Cesano	ZYME	Restricted Stock Unit	Award				7,700	7,700	12 Jan 2026	Direct
Alessandra Cesano	ZYME	Stock Option (Right to Buy)	Award				11,500	11,500	12 Jan 2026	Direct
Carlos Campoy	ZYME	Restricted Stock Unit	Award				7,700	7,700	12 Jan 2026	Direct
Carlos Campoy	ZYME	Stock Option (Right to Buy)	Award				11,500	11,500	12 Jan 2026	Direct
Susan Mahony	ZYME	Restricted Stock Unit	Award				7,700	7,700	12 Jan 2026	Direct
Susan Mahony	ZYME	Stock Option (Right to Buy)	Award				11,500	11,500	12 Jan 2026	Direct
Paul Andrew Moore	ZYME	Common Stock	Sale	-16.5%	$216,759	$22.67	-9,560	48,497	12 Jan 2026	Direct
Paul Andrew Moore	ZYME	Common Stock	Options Exercise	43.7%			17,666	58,057	12 Jan 2026	Direct
Paul Andrew Moore	ZYME	Performance Stock Unit	Award				66,000	66,000	12 Jan 2026	Direct
Paul Andrew Moore	ZYME	Restricted Stock Unit	Award				47,000	47,000	12 Jan 2026	Direct
Paul Andrew Moore	ZYME	Stock Option (Right to Buy)	Award				70,000	70,000	12 Jan 2026	Direct
Paul Andrew Moore	ZYME	Restricted Stock Unit	Options Exercise	-33.3%			-17,666	35,334	12 Jan 2026	Direct
Kenneth Galbraith	ZYME	Common Stock	Sale	-11.8%	$689,819	$22.67	-30,424	226,842	12 Jan 2026	Direct
Kenneth Galbraith	ZYME	Common Stock	Options Exercise	33.1%			64,000	257,266	12 Jan 2026	Direct
Kenneth Galbraith	ZYME	Performance Stock Unit	Award				222,000	222,000	12 Jan 2026	Direct
Kenneth Galbraith	ZYME	Restricted Stock Unit	Award				144,000	144,000	12 Jan 2026	Direct
Kenneth Galbraith	ZYME	Stock Option (Right to Buy)	Award				216,000	216,000	12 Jan 2026	Direct
Kenneth Galbraith	ZYME	Restricted Stock Unit	Options Exercise	-33.3%			-64,000	128,000	12 Jan 2026	Direct
Leone D. Patterson	ZYME	Common Stock	Award				459	459	06 Jan 2026	Direct
Smith Jeffrey T. L.	ZYME	Common Stock	Sale	-36.5%	$264,471	$25.10	-10,538	18,352	05 Jan 2026	Direct
Smith Jeffrey T. L.	ZYME	Common Stock	Options Exercise	225%			20,000	28,890	05 Jan 2026	Direct
Smith Jeffrey T. L.	ZYME	Restricted Stock Unit	Options Exercise	-50%			-20,000	20,000	05 Jan 2026	Direct
Kenneth Galbraith	ZYME	Common Stock	Sale	-25.6%	$1,363,841	$25.10	-54,343	158,286	05 Jan 2026	Direct
Kenneth Galbraith	ZYME	Common Stock	Options Exercise	103.4%			114,334	224,952	05 Jan 2026	Direct
Kenneth Galbraith	ZYME	Restricted Stock Unit	Options Exercise	-100%			-114,334	0	05 Jan 2026	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.